SEC Form 4 · accession 0001193125-26-387798
Metagenomi Therapeutics, Inc. · MGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jian Irish
Officer — See Remarks · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 3:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 8, 2026 | S | 2,140 | $1.1584 | D | 375,393 | D | |
| Common StockF2 | holding | — | — | — | 292,714 | I | By Trust | |
| Common stockF3 | holding | — | — | — | 292,713 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
- F2Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Remarks
President and Chief Executive Officer